secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001213900-24-090153
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15
--------------------------------------------------------------------------------

- Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.
- Post-sale shares outstanding 1,496,771; cash balance approximately $7.4M as of Oct 23, 2024.
- Proceeds to fund tecarfarin development and preparation for pivotal Phase 3 trial.
- H.C. Wainwright acted as exclusive sales agent; shelf registration effective March 20, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/0001213900-24-090153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/ea0218502-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-090153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer